Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007788 | 0.94 | ESR1 (0.48) | ESR1ESR2THRATHRBCYP19A1 | |
| SCHEMBL5007978 | 0.89 | ESR1 (0.57) | ESR1ESR2CYP19A1PTGDR2RXRA | |
| SCHEMBL5011891 | 0.86 | ESR1 (0.53) | ESR1ESR2THRATHRBCYP19A1 | |
| SCHEMBL5007263 | 0.84 | KMT2A (0.57) | ESR1ESR2THRATHRBCYP19A1 | |
| SCHEMBL5007980 | 0.83 | ESR1 (0.49) | ESR1ESR2THRATHRBCYP19A1 | |
| SCHEMBL5010234 | 0.79 | ESR1 (0.51) | ESR1ESR2THRATHRBCYP19A1 | |
| SCHEMBL3827799 | 0.78 | ESR1 (0.70) | ESR1ESR2CYP19A1PTGS2 | |
| SCHEMBL4665812 | 0.78 | ESR1 (0.60) | ESR1ESR2CYP19A1PTGS2 | |
| SCHEMBL5049932 | 0.77 | ESR1 (0.50) | ESR1ESR2PTGS2HSD17B3 | |
| SCHEMBL5049936 | 0.77 | ESR1 (0.50) | ESR1ESR2PTGS2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885ESR2 2/4885THRA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.